Overview of receptor allosterism

Current Protocols in Pharmacology

Volumn , Issue SUPPL.51, 2010, Pages

  Gregory, Karen J ^a   Sexton, Patrick M ^a   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Allosteric ternary complex model; Bitopic; G protein coupled receptor; Modulator; Orthosteric; Radioligand binding

Indexed keywords

1 (3 METHOXYPHENYL) N (3 PHENYLPROPYL)ETHYLAMINE; 1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 2 AMINO 3 (3,4 DICHLOROBENZOYL) 4,5,6,7 TETRAHYDROBENZO[B]THIOPHENE; 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 2 CHLORO 6 [3 [1,1 DIMETHYL 2 (2 NAPHTHYL)ETHYLAMINO] 2 HYDROXYPROPOXY]BENZONITRILE; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2,6 DI TERT BUTYL 4 (3 HYDROXY 2,2 DIMETHYLPROPYL)PHENOL; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; 4 ANILINO 2 CYCLOPENTYLIMIDAZO[4,5 C]QUINOLINE; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 8 (2,4 DICHLOROPHENYL) 4 [2 METHOXY 1 (METHOXYMETHYL)ETHYLAMINO] 2,7 DIMETHYLPYRAZOLO[1,5 A][1,3,5]TRIAZINE; ACETYLCHOLINE; ACETYLSALICYLIC ACID; ADENOSINE RECEPTOR AFFECTING AGENT; AGMATINE; AK 530; AMILORIDE; AMN 082; APLAVIROC; ARECOLINE; ATROPINE; BAY 279955; BAY 367620; BENZODIAZEPINE DERIVATIVE; CARBACHOL; CGP 13501; CP 481715; FURTRETHONIUM; G PROTEIN COUPLED RECEPTOR; GALLAMINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPARIN; L 168049; LIGAND; LY 181837; LY 2033298; LY 487379; METHYLFURTRETHONIUM; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; N,N' DICYCLOPENTYL 2 METHYLTHIO 5 NITRO 4,6 PYRIMIDINEDIAMINE; NBI 2791; NBI 35965; NPS 2390; OLEAMIDE; ORG 27569; ORG 27759; ORG 29647; ORG 41841; PSNCBAM 1; RADIOLIGAND; REPARIXIN; RO 016128; RO 677476; RTI 371; SALICYLATE SODIUM; SB 656933; SCH 527123; T 0632; TAKK 220; TECALCET; UCB 35625; UNCLASSIFIED DRUG; VU 5455; VU 8504; ZINC;

ALLOSTERIC INTERACTION; ALLOSTERIC TRANSITION; ALLOSTERISM; DRUG BINDING SITE; DRUG DETERMINATION; DRUG RECEPTOR BINDING; HETEROTROPIC; HOMOTROPIC; HUMAN; MODULATION; ORTHOSTERIC SITE; PHARMACOLOGY; PRIORITY JOURNAL; RADIOASSAY; REVIEW;

EID: 79953282388     PISSN: 19348282     EISSN: 19348290     Source Type: Journal    
DOI: 10.1002/0471141755.ph0121s51     Document Type: Review

References (51)

1. Antony, J., Kellershohn, K., Mohr-Andrä, M., Kebig, A., Prilla, S., Muth, M., Heller, E., Disingrini, T., Dallanoce, C., Bertoni, S., Schrobang, J., Tränkle, C., Kostenis, E., Christopoulos, A., Höltje, H.D., Barocelli, E., De Amici, M., Holzgrabe, U., and Mohr, K. 2009. Dualsteric GPCR targeting: A novel route to binding and signaling pathway selectivity. FASEB J. 23:442-450.
2. Aurelio, L., Valant, C., Flynn, B.L., Sexton, P.M., Christopoulos, A., and Scammells, P.J. 2009. Allosteric modulators of the adenosine A1 receptor: Synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J. Med. Chem. 52:4543-4547.
3. Avlani, V., May, L.T., Sexton, P.M., and Christopoulos, A. 2004. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 308:1062-1072.
4. Barcroft, J. and Hill, A.V. 1910. The nature of oxyhaemoglobin, with a note on its molecular weight. J. Physiol. 39:411-428.
5. Black, J.W. and Leff, P. 1983. Operational models of pharmacological agonism. Proc. R. Soc. Lond. B. Biol. Sci. 220:141-162.
6. 1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 38:939-949.
7. Chan, W.Y., McKinzie, D.L., Bose, S., Mitchell, S.N., Witkin, J.M., Thompson, R.C., Christopoulos, A., Lazareno, S., Birdsall, N.J., Bymaster, F.P., and Felder, C.C. 2008. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl. Acad. Sci. U.S.A.105:10978-10983.
8. Christopoulos, A. and El-Fakahany, E.E. 1999. Qualitative and quantitative assessment of relative agonist efficacy. Biochem. Pharmacol. 58:735-748.
9. Colquhoun, D. 1973. The relation between classical and cooperative models for drug action. In Drug Receptors (H.P. Rang, ed.) pp. 149-182. Macmillan Press, London.
10. Colquhoun, D. 1998. Binding, gating, affinity and efficacy: The interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br. J. Pharmac. 125:924-947.
11. Disingrini, T., Muth, M., Dallanoce, C., Barocelli, E., Bertoni, S., Kellershohn, K., Mohr, K., De Amici, M., and Holzgrabe, U. 2006. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. J. Med. Chem. 49:366-372.
12. Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A., and Perros, M. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
13. Ehlert, F.J. 1985. The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol. Pharmacol. 28:410-421.
14. Ehlert, F.J. 1988. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33:187-194.
15. Ehlert F.J. and Rathbun, B.E. 1990. Signaling through the muscarinic receptor-adenylate cyclase system of the heart is buffered against GTP over a range of concentrations. Mol. Pharmacol. 38:148-158.
16. Hall, D.A. 2000. Modeling the functional effects of allosteric modulators at pharmacological receptors: An extension of the two-state model of receptor activation. Mol. Pharmacol. 58:1412-1423.
17. 7 receptors. Biochem. Pharmacol. 58:1807-1813.
18. Hejnova, L., Tucek, S., and El-Fakahany, E.E. 1995. Positive and negative allosteric interactions on muscarinic receptors. Eur. J. Pharmacol. 291:427-430.
19. 2 dopamine receptors by amiloride and amiloride analogs. Mol. Pharmacol. 50:1295-1308.
20. Jager, D., Schmalenbach, C., Prilla, S., Schrobang, J., Kebig, A., Sennwitz, M., Heller, E., Trankle, C., Holzgrabe, U., Holtje, H.D., and Mohr, K. 2007. Allosteric small molecules unveil a role of an extracellular E2/transmembrane helix 7 junction for G protein-coupled receptor activation. J. Biol. Chem. 282:34968-34976.
21. Jakub̀ik, J., Bacakova, L., El-Fakahany, E.E., and Tucek, S. 1997. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 52:172-179.
22. Jones, C.K., Brady, A.E., Davis, A.A., Xiang, Z., Bubser, M., Tantawy, M.N., Kane, A.S., Bridges, T.M., Kennedy, J.P., Bradley, S.R., Peterson, T.E., Ansari, M.S., Baldwin, R.M., Kessler, R.M., Deutch, A.Y., Lah, J.J., Levey, A.I., Lindsley, C.W., and Conn, P.J. 2008. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 28:10422-10433.
23. Karlin, A. 1967. On the application of "a Plausible Model" of allosteric proteins to the receptor for acetylcholine. J. Theor. Biol. 16:306-320.
24. Kenakin, T.P. 1997. Pharmacologic Analysis of Drug-Receptor Interaction, 3rd ed. Lippincott-Raven, Philadelphia.
25. Kostenis, E. and Mohr, K. 1996. Composite action of allosteric modulators on ligand binding. Trends Pharmacol. Sci. 17:443-444.
26. Langmead, C.J., Watson, J., and Reavill, C. 2008. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther. 117:232-243.
27. Lazareno, S. and Birdsall, N.J.M. 1995. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 48:362-378.
28. Lazareno, S., Dolezal, V., Popham, A., and Birdsall, N.J. 2004. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: Receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 65:257-266.
29. Leach, K., Sexton, P.M., and Christopoulos, A. 2007. Allosteric GPCR modulators: Taking advantage of permissive receptor pharmacology. Trends. Pharmacol. Sci. 28:382-389.
30. Lefkowitz, R.J., Cotecchia, S., Samama, P., and Costa, T. 1993. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14:303-307.
31. 2A-adrenergic receptor. Mol. Pharmacol. 53:916-925.
32. Lindberg, J. S., Culleton, B., Wong, G., Borah, M.F., Clark, R.V., Shapiro, W.B., Roger, S.D., Husserl, F.E., Klassen, P.S., Guo, M.D., Albizem, M.B., and Coburn, J.W. 2005. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J. Am. Soc. Nephrol. 16:800-807.
33. May, L.T., Avlani, V.A., Langmead, C.J., Herdon, H.J., Wood, M.D., Sexton, P.M., and Christopoulos, A. 2007. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol. Pharmacol. 72:463-476.
34. Milligan, G. and Smith, N.J. 2007. Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends. Pharmacol. Sci. 28:615-620.
35. Monod, J. and Jacob, F. 1961. General conclusions: Teleonomic mechanisms in cellular metabolism, growth, and differentiation. Cold Spring Harbor Symp. Quant. Biol. 26:389-401.
36. Monod, J., Changeux, J.-P., and Jacob, F. 1963. Allosteric proteins and cellular control systems. J. Mol. Biol. 6:306-329.
37. Monod, J., Wyman, J., and Changeux, J.P. 1965. On the nature of allosteric transitions: A plausible model. J. Mol. Biol. 12:88-118.
38. Nawaratne, V., Leach, K., Suratman, N., Loiacono, R.E., Felder, C.C., Armbruster, B.N., Roth, B.L., Sexton, P.M., and Christopoulos, A. 2008. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol. Pharmacol. 74:1119-1131.
39. Neubig, R.R., Spedding, M., Kenakin, T., and Christopoulos, A. 2003. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 55:597-606.
40. Price, M.R., Baillie, G.L., Thomas, A., Stevenson, L.A., Easson, M., Goodwin, R., McLean, A., McIntosh, L., Goodwin, G., Walker, G., Westwood, P., Marrs, J., Thomson, F., Cowley, P., Christopoulos, A., Pertwee, R.G., and Ross, R.A. 2005. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 68:1484-1495.
41. Proska, J. and Tucek, S. 1994. Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. Mol. Pharmacol. 45:709-717.
42. Spalding, T.A., Trotter, C., Skjaerbaek, N., Messier, T.L., Currier, E.A., Burstein, E.S., Li, D., Hacksell, U., and Brann, M.R. 2002. Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol. Pharmacol. 61:1297-1302.
43. Spalding, T.A., Ma, J.N., Ott, T.R., Friberg, M., Bajpai, A., Bradley, S.R., Davis, R.E., Brann, M.R., and Burstein, E.S. 2006. Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: Evidence for three distinct modes of receptor activation. Mol. Pharmacol. 70:1974-1983.
44. Thron, C.D. 1973. On the analysis of pharmacological experiments in terms of an allosteric receptor model. Mol. Pharmacol. 9:1-9.
45. Urwyler, S., Mosbacher, J., Lingenhoehl, K., Heid, J., Hofstetter, K., Froestl, W., Bettler, B., and Kaupmann, K. 2001. Positive allosteric modulation of native and recombinant gamma-aminobutyric acid(B) receptors by 2,6-Di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol. Pharmacol. 60:963-971.
46. Valant, C., Gregory, K.J., Hall, N.E., Scammells, P.J., Lew, M.J., Sexton, P.M., and Christopoulos, A. 2008. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. 283:29312-29321.
47. Valant, C., Sexton, P.M., and Christopoulos, A. 2009. Orthosteric/allosteric bitopic ligands: Going hybrid at GPCRs. Mol. Interv. 9:125-135.
48. Weber, G. 1972. Ligand binding and internal equilibria in proteins. Biochemistry 11:864-878.
49. Weber, G. 1975. Energetics of ligand binding to proteins. Adv. Prot. Chem. 29:1-83.
50. Wyman, J. 1975. The turning wheel: A study in steady states. Proc. Natl. Acad. Sci. U.S.A. 72:3983-3987.
51. Zahn, K., Eckstein, N., Trankle, C., Sadee, W., and Mohr, K. 2002. Allosteric modulation of muscarinic receptor signaling: Alcuronium-induced conversion of pilocarpine from an agonist into an antagonist. J. Pharmacol. Exp. Ther. 301:720-728.